Vascular Graft Articles & Analysis
29 news found
While countless applications are still being explored, hydrophobic polymers, which are insoluble in water and other polar solvents, are commonly used as coatings, adhesives, fibers, films, and engineering plastics, in addition to biomedical polymers for vascular grafts, implants, and ophthalmic applications. “Our experts are devoted to functionalizing ...
The company, headquartered in Milan, Italy, currently has several assets under development, such as vascular graft, bone graft substitutes, rotator cuff repair, drug release. ...
ByKLISBio
KLISBio is targeting a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained drug release is needed. ...
ByKLISBio
KLISBio is leveraging silk as a powerful and biocompatible scaffold material, targeting different clinical indications in the orthopedic, vascular and drug release markets via several technology platforms.”, said Jason Schense, CBO and COO. KLISBio is focused on healing and regenerating human body tissues by developing innovative solutions that solve prominent, unmet ...
ByKLISBio
KLISBio is focused on developing innovative solutions that solve prominent unmet clinical needs through a silk-based multidisciplinary technology platform able to generate products and solutions for a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained drug release is needed. ...
ByKLISBio
The company, headquartered in Milan, Italy, currently has several assets under development, such as vascular graft, bone graft substitutes, rotator cuff repair, drug release. ...
ByKLISBio
“KLISBio is focused on developing innovative solutions to tackle prominent unmet clinical needs through a silk-based multidisciplinary technology platform able to generate products and solutions for a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained drug release is ...
ByKLISBio
KLISBio will introduce SILKBridge® to attendees at the American Association for Hand Surgeons Annual Meeting Jan. 12-15, 2022. SILKBridge®, a silk-based graft, is a tissue-engineered technology based on pure silk fibroin. ...
ByKLISBio
Among the company’s developing portfolio of products is SILKBridge®, a first-to-market, silk-based graft for peripheral nerve repair, which is anticipated to be available for clinical use in 2023. ...
ByKLISBio
Engineered silk materials provide a unique combination of outstanding biological and mechanical properties for a variety of clinical indications such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained drug release is needed. ...
ByKLISBio
The GOAL Study is an independent investigator observational clinical study to assess the role of vascular graft /storage solutions on myocardial protection during coronary artery bypass grafting (CABG) surgeries. ...
The allowed DuraGraft® related patent applications cover an organ and tissue preservation kit containing shelf-life stable solutions used for vascular graft and tissue protection and preservation during bypass and other vascular surgeries. These patents protect Marizyme’s flagship commercial product DuraGraft®, a first-in-class CE ...
” Xeltis’ devices are vascular grafts and heart valves designed to turn into living valves and vessels by harnessing the body’s natural healing process and by facilitating tissue formation once implanted. ...
The Company's flagship product, DuraGraft®, is an intra-operative vascular graft storage solution that inhibits endothelial damage and leads to improved clinical outcomes by reducing the incidence of complications associated with vein graft failure in bypass surgery. DuraGraft enhances coronary artery bypass grafting (CABG) ...
In addition to its restorative pulmonary valve, Xeltis has developed the first-ever restorative synthetic coronary artery bypass graft (CABG) to have shown successful long-term results in long preclinical trials and the first-ever restorative synthetic vascular access graft for patients that need ...
Healionics is preparing to commercialize its innovative STARgraft vascular graft, designed to provide a safer and more reliable means to access the bloodstream for dialysis in patients with kidney failure. ...
"DuraGraft will enhance coronary artery bypass grafting (CABG) surgical outcomes by significantly reducing major adverse cardiac events such as repeat revascularization and myocardial infarction, providing better patient care, and potentially lowering the impact on the overall cost of health care in CABG procedures." ...
(OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has named veteran business executive Julie Kampf as an Independent Member of its Board of Directors. ...
(OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has added two life science industry veterans to its senior management team. ...
India represents the latest market approval for DuraGraft, a CE-marked product that protects vascular grafts against ischemic injury and is the only product approved for graft protection and preservation during bypass and other vascular surgeries. ...